Upstart earnings missed by $0.41, revenue topped estimates

Upstart (UPST) reported mixed second-quarter results, significantly missing EPS estimates at $-0.17 against a consensus of $0.24, yet exceeding revenue expectations with $257 million versus $225.43 million. The company also provided robust Q3 and FY 2025 revenue guidance that surpassed analyst consensus. This performance, characterized by an earnings miss but strong top-line growth and optimistic forward guidance, presents a nuanced investment case, particularly given the stock's substantial 246% appreciation over the past year and its 'fair performance' financial health rating.

Analysis

Upstart Holdings (UPST) presented a dichotomous second-quarter financial report, characterized by a significant earnings per share miss but a strong top-line performance and optimistic forward guidance. The company reported an EPS of $-0.17, which was $0.41 below the analyst consensus of $0.24, indicating substantial pressure on profitability. Conversely, revenue for the quarter came in at $257 million, comfortably beating the $225.43 million estimate. Management extended this positive revenue outlook, guiding for Q3 2025 revenue of $280 million and full-year 2025 revenue of $1.06 billion, both surpassing consensus forecasts. This mixed fundamental picture is set against a backdrop of extreme stock price appreciation, with a 246.12% gain over the last 12 months. However, caution is warranted due to several underlying factors: the company's financial health is rated as only "fair performance," and analyst sentiment is split, with an equal number of positive and negative EPS revisions over the past 90 days, suggesting a lack of consensus on its earnings trajectory.

Key Decisions for Investors

• Investors focused on growth may see the strong revenue beat and bullish forward guidance as the primary drivers, potentially overlooking the earnings miss as a short-term issue.
• Given the stock's 246% appreciation in the last year, the significant EPS miss and 'fair' financial health rating signal that the valuation may be stretched, suggesting caution for new or risk-averse investors.
• Current holders should monitor whether the company can translate its strong revenue growth into improved profitability in coming quarters, as the split in analyst revisions indicates significant uncertainty in the earnings outlook.